Taysha Gene Therapies/$TSHA
1D1W1MYTD1Y5YMAX
Capital at risk
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
- Ticker
- $TSHA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 99
- Headquarters
- Dallas, United States
- Website
- www.tayshagtx.com
TSHA Metrics
BasicAdvanced
$1.6B
-
-$0.41
1.19
-
Price and volume
Market cap
$1.6B
Beta
1.19
52-week high
$7.30
52-week low
$2.71
Average daily volume
2.5M
Financial strength
Current ratio
17.765
Quick ratio
17.533
Long term debt to equity
0.143
Total debt to equity
0.146
Interest coverage (TTM)
-3,646.64%
Profitability
EBITDA (TTM)
-151.988
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-2,728.04%
Operating margin (TTM)
-2,792.32%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-23.82%
Return on equity (TTM)
-47.05%
Valuation
Price to revenue (TTM)
330.453
Price to book
4.21
Price to tangible book (TTM)
4.21
Price to free cash flow (TTM)
-13.369
Free cash flow yield (TTM)
-7.48%
Free cash flow per share (TTM)
-0.375
Growth
Revenue change (TTM)
-32.27%
Earnings per share change (TTM)
23.11%
3-year revenue growth (CAGR)
-17.03%
3-year earnings per share growth (CAGR)
-42.73%
What the Analysts think about TSHA
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
Analyst projections of the future price of Taysha Gene Therapies stock.
Bulls say / Bears say
Completed dosing in the overenrolled REVEAL pivotal trial of TSHA-102 for Rett syndrome, advancing the program toward potential regulatory submission. (Thomson Reuters)
TSHA-102 demonstrated no treatment-related serious adverse events or dose-limiting toxicities across ongoing REVEAL trials, underscoring a favorable safety profile. (Thomson Reuters)
Topline data and FDA feedback on the BLA submission pathway for TSHA-102 are expected in the first half of 2027, providing clarity on the regulatory timeline. (Thomson Reuters)
Taysha’s Q2 net loss widened to $46.6 million versus analyst estimates of $42.7 million, triggering an 8.7% share decline in pre-market trading. (Reuters)
The company launched a $200 million common stock and pre-funded warrants offering, raising dilution concerns for existing shareholders. (Thomson Reuters)
Taysha granted 714,700 RSUs and 468,600 stock options to new hires under an inducement plan, potentially increasing share count and diluting equity. (Thomson Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
TSHA Financial Performance
Revenues and expenses
TSHA Earnings Performance
Company profitability
Upcoming events
No upcoming events
TSHA News
AllArticlesVideos
Funds containing TSHA
AllUSDEURGBP
Fund name | Fund size | $TSHA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.15% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.15% |
iShares Healthcare Innovation£DRDR | £1B | 0.15% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
iShares Ageing Population€AGED | €822M | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.